VentiRx Pharmaceuticals Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 19

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $35M

VentiRx Pharmaceuticals General Information

Description

Developer of small molecule product candidates designed to treat cancer. The company's small molecule product candidates target Toll-like receptor 8 (TLR8), enabling cancer patients to get improved treatment.

Contact Information

Website
www.ventirx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1191 Second Avenue
  • Suite 1105
  • Seattle, WA 98101
  • United States
+1 (206)
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • 1191 Second Avenue
  • Suite 1105
  • Seattle, WA 98101
  • United States
+1 (206)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VentiRx Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 20-Jan-2017 $35M Completed Generating Revenue
5. Later Stage VC (Series B) 30-Sep-2014 Completed Generating Revenue
4. Later Stage VC 03-Oct-2012 Completed Generating Revenue
3. Early Stage VC (Series A) 12-Jan-2010 Completed Startup
2. Early Stage VC (Series A) 06-Mar-2007 $26.6M $28.9M Completed Startup
1. Seed Round 26-Jun-2006 $2.31M $2.31M Completed Startup
To view VentiRx Pharmaceuticals’s complete valuation and funding history, request access »

VentiRx Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Series 1 2,312,500 $0.000100 $0.08 $1 $1 1x $1 4.79%
To view VentiRx Pharmaceuticals’s complete cap table history, request access »

VentiRx Pharmaceuticals Patents

VentiRx Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2018532803-A Use of a tlr8 agonist to treat cancer Pending 02-Nov-2015
CA-3003948-A1 Use of tlr8 agonists to treat cancer Inactive 02-Nov-2015
EP-3370726-A1 Use of tlr8 agonists to treat cancer Inactive 02-Nov-2015
EP-3370726-A4 Use of tlr8 agonists to treat cancer Inactive 02-Nov-2015
US-20180303845-A1 Use of tlr8 agonists to treat cancer Inactive 02-Nov-2015 A61K31/55
To view VentiRx Pharmaceuticals’s complete patent history, request access »

VentiRx Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VentiRx Pharmaceuticals Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
Domain Associates Venture Capital Minority
Frazier Healthcare Partners PE/Buyout Minority
MedImmune Ventures Corporate Venture Capital Minority
To view VentiRx Pharmaceuticals’s complete investors history, request access »

VentiRx Pharmaceuticals FAQs

  • When was VentiRx Pharmaceuticals founded?

    VentiRx Pharmaceuticals was founded in 2006.

  • Where is VentiRx Pharmaceuticals headquartered?

    VentiRx Pharmaceuticals is headquartered in Seattle, WA.

  • What is the size of VentiRx Pharmaceuticals?

    VentiRx Pharmaceuticals has 19 total employees.

  • What industry is VentiRx Pharmaceuticals in?

    VentiRx Pharmaceuticals’s primary industry is Biotechnology.

  • Is VentiRx Pharmaceuticals a private or public company?

    VentiRx Pharmaceuticals is a Private company.

  • What is the current valuation of VentiRx Pharmaceuticals?

    The current valuation of VentiRx Pharmaceuticals is .

  • What is VentiRx Pharmaceuticals’s current revenue?

    The current revenue for VentiRx Pharmaceuticals is .

  • How much funding has VentiRx Pharmaceuticals raised over time?

    VentiRx Pharmaceuticals has raised $104M.

  • Who are VentiRx Pharmaceuticals’s investors?

    ARCH Venture Partners, Domain Associates, Frazier Healthcare Partners, and MedImmune Ventures have invested in VentiRx Pharmaceuticals.

  • When was VentiRx Pharmaceuticals acquired?

    VentiRx Pharmaceuticals was acquired on 20-Jan-2017.

  • Who acquired VentiRx Pharmaceuticals?

    VentiRx Pharmaceuticals was acquired by Celgene.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process